Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01211860 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study of Diazoxide Choline in Hypertriglyeridemic Subjects
A Phase 1 study, sponsored by Essentialis.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01211860: Completed Phase 1 study, sponsored by Essentialis.
NCT01211860 is a Phase 1 study that has completed, run by Essentialis. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01211860, a Phase 1 study, has completed, sponsored by Essentialis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
Once a day oral administration with DCCR is the optimal dosing regimen
Primary Outcome
* Mean concentration-time profile for diazoxide * Steady-state pharmacokinetic parameters of diazoxide (Cmax(ss), AUC0-inf(ss), and CL/F) * Terminal elimination half-life (t½) of diazoxide
Interventions
- DRUG Diazoxide Choline Controlled-Release Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2010-10 |
| Est. Completion | 2010-11 |
| Phase | Phase 1 |
What the finished NCT01211860 record still lists
NCT01211860 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which Diazoxide Choline Controlled-Release Tablet is the first listed.
NCT01211860 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01211860 about?
NCT01211860 is a clinical study titled "Pharmacokinetic Study of Diazoxide Choline in Hypertriglyeridemic Subjects". Once a day oral administration with DCCR is the optimal dosing regimen
What is the current status of trial NCT01211860?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2010-10. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01211860?
The interventions under investigation include: Diazoxide Choline Controlled-Release Tablet (DRUG).
Who is sponsoring clinical trial NCT01211860?
This trial is sponsored by Essentialis, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01211860's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia